cct018159 has been researched along with Neoplasms* in 2 studies
2 review(s) available for cct018159 and Neoplasms
Article | Year |
---|---|
[Progress in the study of heat shock protein 90 inhibitors].
Heat shock protein 90 is a new target of antitumor drug, the inhibitor of Hsp90 fight against tumor by destroy and degrade the structure of protein. In recent years, looking for Hsp90 inhibitor is not only via structure modifying of natural products, but also via high throughput screening and computer aided drug design to find and synthesize new kinds of Hsp90 inhibitor. Anyway, Hsp90 inhibitor has considered as an important biology target and to pay more and more attention. This review describes recent developments of small molecule Hsp90 inhibitors. Topics: Adenine; Animals; Anisoles; Antineoplastic Agents; Benzoquinones; Catechin; Cell Line, Tumor; Crystallization; Heterocyclic Compounds, 2-Ring; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Macrolides; Molecular Structure; Neoplasms; Pyrazoles; Structure-Activity Relationship | 2010 |
New approaches to molecular cancer therapeutics.
Cancer drug development is leading the way in exploiting molecular biological and genetic information to develop "personalized" medicine. The new paradigm is to develop agents that target the precise molecular pathology driving the progression of individual cancers. Drug developers have benefited from decades of academic cancer research and from investment in genomics, genetics and automation; their success is exemplified by high-profile drugs such as Herceptin (trastuzumab), Gleevec (imatinib), Tarceva (erlotinib) and Avastin (bevacizumab). However, only 5% of cancer drugs entering clinical trials reach marketing approval. Cancer remains a high unmet medical need, and many potential cancer targets remain undrugged. In this review we assess the status of the discovery and development of small-molecule cancer therapeutics. We show how chemical biology approaches offer techniques for interconnecting elements of the traditional linear progression from gene to drug, thereby providing a basis for increasing speed and success in cancer drug discovery. Topics: Drug Design; Genome; Humans; Neoplasms; Structure-Activity Relationship | 2006 |